ADP receptors : inhibitory strategies for antiplatelet therapy

The interaction of adenosine-5'-diphosphate (ADP) with its platelet receptors (P2Y1 and P2Y12) plays a very important role in thrombogenesis. The thienopyridine ticlopidine was the first specific antagonist of the platelet P2Y12 ADP receptor to be tested in randomized clin. trials for the prevention of arterial thrombotic events. Although ticlopidine reduces the incidence of vascular events in patients at risk, it also unfortunately has some significant drawbacks: a relatively high incidence of toxic effects, which may be fatal in some cases; delayed onset of action; and a high interindividual variability in response. A second thienopyridine, clopidogrel, has superseded ticlopidine, because it is also an efficacious antithrombotic drug and is less toxic than ticlopidine. However, clopidogrel is not completely free from faults: severe toxic effects, albeit occurring much less frequently than with ticlopidine, may still complicate its administration to patients; the onset of pharmacol. action can be accelerated by the use of large loading doses, but may still not be optimal; the high interpatient variability in response remains an important issue. These concerns justify the continued search for agents that can further improve the clin. outcome of patients with atherosclerosis through greater efficacy and/or safety. A new thienopyridyl compd., prasugrel, which is characterized by higher potency and faster onset of action compared with clopidogrel, is currently under clin. evaluation. Two direct and reversible P2Y12 antagonists, cangrelor and AZD6140, feature very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, esp. when rapid inhibition of platelet aggregation or its quick reversal are required. Along with new the P2Y12 antagonists, inhibitors of the other platelet receptor for ADP, the antagonists P2Y1, are under development and may prove to be effective antithrombotic agents